Recent Developments in Biologic Therapies for the Treatment of Patients With Systemic Lupus Erythematosus

Pedro L. Carreira; David A. Isenberg


Rheumatology. 2019;58(3):382-387. 

In This Article


Biologic treatment of lupus has seen many false dawns. The relative successes of belimumab, rituximab, and atacicept (not discussed here) have been counterbalanced by the failures of many others including abatacept, tabalumab, blisibimod, and epratuzumab. But a number of new approaches, including fully humanized anti-CD20, PEGylated anti-CD40L, IFNα inhibitors and rigerimod, offer new hope that before too long we will have a range of biologic options to offer our SLE patients that matches the choices we have for our RA and PSA patients.

Other approaches, not discussed here, such as blocking the Janus kinase/signal transducers and activators of transcription-pathway, Il-6 and nuclear factor kappa-light-chain-enhancer of activated B cells might also prove of value.